Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
Stockholders Equity Over TimeExpanding
Percentile Rank100
5Y CAGR+40.3%
Studio
Year-over-Year Change

Net worth of the company (assets minus liabilities)

5Y CAGR
+40.3%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
5.4x
Strong expansion
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$459.60M+48.3%
2024$309.85M+26.0%
2023$245.91M+420.1%
2022$-76.83M-171.9%
2021$106.86M+26.6%
2020$84.44M+272.9%
2019$-48.85M-85.6%
2018$-26.32M-69.4%
2017$-15.53M-